NCT06236724View on ClinicalTrials.gov

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

PHASE2RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

July 1, 2033

Study Completion Date

July 1, 2035

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

Asciminib

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER